Hematology
Clinical
DOACs for treatment of cancer-associated venous thromboembolism
Recent studies suggest DOACs may be a viable option in the treatment of malignancy-associated VTE.
News
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
News
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...
News
Transfusion-related lung injury is on the rise in elderly patients
SAN ANTONIO – Researchers at the Food and Drug Administration examined trends in potentially life-threatening or fatal transfusion-related adverse...
All Content
Dose-reduced NOACs may be safer than warfarin in some AFib patients
Are dose-reduced non–vitamin K antagonist oral anticoagulants (NOACs) safer or more effective than warfarin is in patients with atrial...
News
Updated international consensus recommendations on management of acute upper GI bleeding
Updated guidelines on management of nonvariceal acute upper GI bleeding address questions on endoscopic techniques and pharmacologic management....
News
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
Clinical
Is it safe to discharge patients with anemia?
What is the prevalence of anemia at the time of and after discharge from the hospital, and what is the associated morbidity and mortality at 6...
Clinical
Reversal agents for direct-acting oral anticoagulants
DOACs are increasingly prescribed for anticoagulation, thanks to its multiple advantages.
News
NOACs benefit early stage chronic kidney disease patients
NOACs reduced risk of several adverse events compared with VKAs in a meta-analysis of chronic kidney disease patients.